Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
Top Cited Papers
Open Access
- 1 February 2010
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 33 (2), 428-433
- https://doi.org/10.2337/dc09-1499
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapiesJournal of the American Society of Hypertension, 2009
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)The Lancet, 2009
- Glucagon-Like Peptide-1 Receptor Activation Modulates Pancreatitis-Associated Gene Expression But Does Not Modify the Susceptibility to Experimental Pancreatitis in MiceDiabetes, 2009
- Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 DiabetesDiabetes, 2009
- Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 DiabetesDiabetes Care, 2009
- GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in MiceDiabetes, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Prognosis of medullary thyroid carcinomaCancer, 2006
- Expression of glucagon‐like peptide 1 receptor in a murine C cell line Regulation of calcitonin gene by glucagon‐like peptide 1FEBS Letters, 1996